Appenzeller, Silke <br/><br/>
The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.  [electronic resource] 

 -  Cancer  02 2019 
 - 586-600 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.31843  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Biomarkers, Tumor--genetics<br/>Case-Control Studies<br/>Cyclin-Dependent Kinase 4--genetics<br/>DNA Copy Number Variations<br/>Follow-Up Studies<br/>GTP Phosphohydrolases--genetics<br/>Gene Expression Regulation, Neoplastic<br/>High-Throughput Nucleotide Sequencing<br/>Humans<br/>Melanoma--genetics<br/>Membrane Proteins--genetics<br/>Mutation<br/>Prognosis<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Proto-Oncogene Proteins c-kit--genetics<br/>Receptor, ErbB-2--genetics<br/>Skin Neoplasms--genetics